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Abstract
There is a consistent demand for new biosensors for the detection of protein targets, and a systematic method for the rapid
development of new sensors is needed. Here we present a platform where short unstructured peptides that bind to a
desired target are selected using M13 phage display. The selected peptides are then chemically synthesized and
immobilized on gold, allowing for detection of the target using electrochemical techniques such as electrochemical
impedance spectroscopy (EIS). A quartz crystal microbalance (QCM) is also used as a diagnostic tool during biosensor
development. We demonstrate the utility of this approach by creating a novel peptide-based electrochemical biosensor for
the enzyme alanine aminotransferase (ALT), a well-known biomarker of hepatotoxicity. Biopanning of the M13 phage
display library over immobilized ALT, led to the rapid identification of a new peptide (ALT5-8) with an amino acid sequence
of WHWRNPDFWYLK. Phage particles expressing this peptide exhibited nanomolar affinity for immobilized ALT
(Kd,app=85620 nM). The newly identified ALT5-8 peptide was then chemically synthesized with a C-terminal cysteine for
gold immobilization. The performance of the gold-immobilized peptides was studied with cyclic voltammetry (CV), QCM,
and EIS. Using QCM, the sensitivity for ALT detection was 8.960.9 Hz/(mg/mL) and the limit of detection (LOD) was 60 ng/
mL. Using EIS measurements, the sensitivity was 142612 impedance percentage change %/(mg/mL) and the LOD was
92 ng/mL. In both cases, the LOD was below the typical concentration of ALT in human blood. Although both QCM and EIS
produced similar LODs, EIS is preferable due to a larger linear dynamic range. Using QCM, the immobilized peptide
exhibited a nanomolar dissociation constant for ALT (Kd=20.160.6 nM). These results demonstrate a simple and rapid
platform for developing and assessing the performance of sensitive, peptide-based biosensors for new protein targets.
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Introduction
A biosensor is an analytical device that combines a
recognition element with a transducer (detection element) for
the detection of a biological analyte (target) [1,2]. The
recognition process utilizes the affinity of the recognition
element to the analyte and the interaction information is
transmitted as a measurable signal (electrical, optical, etc.) by
the transducer. The overall selectivity and the sensitivity of the
biosensor are dependent on both the recognition element and
the transducer. In this work, we demonstrate a general pathway
for the development of new biosensors utilizing unstructured
peptides selected using M13 phage display as the recognition
element, QCM as a diagnostic tool during development, and
electrochemical techniques (CV, EIS) as the detection elements.
This procedure is fast and can be applied to almost any desired
protein target (Figure 1A).
Immunosensors are commonly used biosensors that rely on
antibodies as the biomolecular recognition element and require
multi-step processing and labeling of the samples [3]. The
widespread use of antibody-based immunoassays has been
hindered by their high cost and the significant time necessary to
develop new antibodies to emerging targets [4]. Several efforts
have been made to address these limitations on the biomolecular
recognition element, including the use of nucleic acid-based
aptamers [5] alternative protein scaffolds [6], and short unstruc-
tured peptides [4,7]. Compared to more complex protein-based
affinity scaffolds, short unstructured peptides have several potential
advantages that can be exploited for biosensor development: 1)
peptides are stable and resistant to harsh environments, 2) peptides
can be synthesized easily and inexpensively, and 3) peptides can be
more amenable than antibodies to engineering at the molecular
level [8,9,10]. In addition, the immobilization of short peptides on
gold electrodes for use as the recognition element has been well
characterized since the early 80’s [11,12].
Biopanning of phage displayed peptide libraries is a widely
utilized method that allows for the rapid selection of peptides that
bind to desired protein targets. Several groups have reported
biosensors where the entire phage particles from these selections
(featuring multiple copies of the peptides) are employed as the
sensing probes in the biosensors [13,14,15]. Although phage
display has been widely applied to identify peptides or proteins
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phage-bound) peptides in the development of biosensors has been
less frequently reported. Using free peptides can be advantageous
as this can simplify the electrochemical detection techniques. As
an example of this approach, we have recently described a new
biosensor for the detection of troponin I (a cardiac biomarker)
using peptides isolated by M13 phage display [16,17].
The QCM has been widely used in biosensor development
because it is a label-free technique [18,19,20]. The QCM is based
on a piezoelectric material (quartz), where an alternating electrical
field across the quartz creates an alternating shear motion of the
crystal. Through appropriate circuitry, the change in the
resonance frequency, Df, of the crystal is tracked in real time. At
constant temperature, this resonant frequency responds primarily
to the change in mass associated with the crystal surface, Dm, and
changes in the viscoelastic properties of the fluid adjacent to the
crystal (Figure 1B). The relationship between Df and Dm is linear
according to the Sauerbrey equation [16].
Electrochemical techniques can also be used for the creation of
label-free biosensors [21,22,23,24]. They have the potential to be
inexpensive, fast responding, and low maintenance. The most
well-known example of an electrochemical biosensor is the
commercial glucose sensor for diabetes [25,26], where the reaction
product of glucose oxidase with glucose converts ferricyanide to
the electroactive species ferrocyanide that is monitored electro-
chemically. Other applications also benefit from the fact that
biosensing electrodes can be easily integrated into microfabricated
systems and used as portable test tools for field measurements
[27,28].
Cyclic voltammetry (CV) and electrochemical impedance
spectroscopy (EIS) are two frequently used techniques in these
applications. Both techniques measure either the current or the
impedance obtained by varying the applied potential (voltage).
When applied here, the method detects binding of an analyte on
the surface of an electrode by the amount it hinders the access of
an electroactive redox couple (ferri/ferrocyanide, in this case) to
Figure 1. Schematic diagram illustrating the general process of biosensor development. (A) Work flow diagram for biosensor
development: 1. Target protein selection, 2. Phage display selection, 3. Peptide synthesis, 4. QCM diagnosis, 5. Biosensor detection. B) The basic
principle of QCM where the binding of the target protein to the immobilized peptides causes a frequency change in the oscillation of the quartz
crystal. C) The basic principle of EIS where the binding of the target protein to the immobilized peptides causes increased resistance to the reaction of
an added redox couple. See text for details.
doi:10.1371/journal.pone.0024948.g001
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increasing impedance in EIS. CV provides rapid evidence for
binding but it is less quantitative. In EIS, the sinusoidal current
obtained in response to small amplitude, sinusoidal perturbations
of the potential is measured. The current response has an
amplitude relative to the potential amplitude and is also out of
phase from the perturbation. For this reason, results are reported
as complex impedance. It is common to plot EIS data in a Nyquist
plot, and fit them using an equivalent circuit model to extract the
parameter of interest. Here it is the resistance of charge transfer of
the redox couple, which is impacted by bound analyte (Figure 1C).
In this paper, we describe a novel biosensor for the detection of
alanine aminotransferase (ALT, EC 2.6.1.2, also called glutamate
pyruvate transaminase, GPT). ALT catalyzes the reversible
transamination of L-alanine and a-ketoglutarate to pyruvate and
L-glutamate with pyridoxal 59-phosphate as a coenzyme. ALT is
found mainly in the liver, but is also found in red blood cells, heart
cells, muscle tissue and other organs, such as the pancreas and
kidneys [29,30]. Serum ALT levels are an indicator for liver
damage and its detection is considered the gold standard
biomarker of hepatotoxicity [30,31,32]. The normal concentration
of ALT in blood serum ranges from 5–35 U/L (0.1–0.7 mg/mL),
[29] and serum ALT levels increase up to 50-fold in connec-
tion with a variety of liver conditions, including viral infection,
cirrhosis, non-alcoholic steatohepatitis, and drug toxicity [31,33,
34]. Most ALT biosensors are based on the detection of the
enzymatic activity of the ALT enzyme as opposed to the detection
of the protein itself [29,35,36,37].
In this article we present the selection of ALT binding peptides
from an M13 phage displayed peptide library and the character-
ization of the binding affinities of the peptides. Once the most
promising peptide was selected, a cysteine-modified free peptide
was synthesized and transferred to the biosensor platform. The
binding activity was monitored in situ by QCM, and the peptide-
modified gold electrode was used to detect ALT quantitatively
using EIS. The general approach (Figure 1) can be extended to
develop biosensors for a wide variety of target analytes. The
methodology can be easily applied in a relatively short period of
time at low cost.
Materials and Methods
Materials
All reagents used were analytical grade or higher unless otherwise
stated. Escherichia coli strain ER2738, a host for M13 phage, and a
polyvalent M13 phage display kit (Ph.D.-12) which contained
random 12-mer peptides were obtained from New England Biolabs
(Ipswich, MA). ALT (human liver) and lactate dehydrogenase (LDH)
were obtained from Lee Biosolutions, Inc. (St. Louis, Missouri).
Horseradish peroxidase (HRP) conjugated anti-M13 monoclonal
antibody was from GE Healthcare (Piscataway, NJ). Tween 20, 2,29-
Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt
(ABTS), streptavidin (SA) from Streptomyces avidinii,b o v i n es e r u m
albumin (BSA), L-cysteine hydrochloride (98%) and all other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Polystyrene microplates were from Pierce Biotechnology (Rockford,
IL). The ALT5-8 peptide modified with a C-terminal cysteine
(sequence: WHWRNPDFWYLKC) was synthesized (.90% purity)
by Genscript (Piscataway, NJ). Quartz crystals (AT-cut, 5 MHz) with
Au deposited on both sides were obtained from Inficon (East
Syracuse, New York). Buffer solutions (pH=7.3) containing 0.01 M
sodium phosphate and 0.1 M NaCl were used to make all protein (1–
10 mg/mL) and peptide (0.1 mM) solutions for the QCM and EIS
measurements. All solutions were prepared using Milli-Q water.
Biopanning of Phage-Displayed Peptide Library
ALT (2.6 mg/mL) was dissolved in NaHCO3 buffer (100 mM,
pH 8.3) and transferred to the wells of polystyrene microplates.
After overnight incubation with mild agitation at 4uC, the well
surfaces were coated with ALT. The well surfaces were then
blocked with blocking buffer (0.1 M NaHCO3 containing 2% BSA
and 0.02% of NaN3) for 1 hr at 4uC, and washed 6 times with
TBST (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20)
to remove weakly bound ALT. The Ph.D.-12 phage displayed
random peptide library (1.5610
11 pfu) in 100 mL of TBS buffer
(50 mM Tris-HCl pH 7.5, 150 mM NaCl) was added to the ALT
coated wells, and the plate was shaken gently for 1 h at room
temperature. Wells were washed 10 times with TBST to remove
unbound phage. The bound phage were eluted with 100 mLo f
0.2 M glycine-HCl (pH 2.2) and the elution was immediately
neutralized with 15 mL Tris-HCl (1 M, pH 9.1) to prevent phage
killing. The eluted phage were amplified in E. coli ER2738 and the
phage were harvested by precipitation with NaCl/polyethylene
glycol (20% (w/v) polyethylene glycol-8000 with 2.5 M NaCl).
This biopanning process was repeated for five rounds. The
concentration of Tween 20 in the washing step was increased from
0.1% in the first round of panning to 0.3% in the second round of
panning and 0.5% in the final three rounds of panning. After each
round of panning, the phage were titered using Luria-Bertani (LB)
broth plates containing isopropyl b-D-thiogalactopyranoside
(IPTG) and X-gal. After the fifth round of selection, twelve blue
monocolonies were randomly picked and amplified for DNA
sequencing.
ELISA for Peptide Binding to ALT
To test whether or not the selected phage clones from the
biopanning procedure could bind to ALT, ELISA assays were
performed. Microplates were coated with ALT (2.6 mg/mL)
overnight at 4uC, blocked with blocking buffer, and washed 6
times with TBST solution (containing 0.1% Tween 20). Varying
amounts of amplified phage clones were added to each well and
incubated for 1 hr at room temperature. After washing, HRP-
conjugated anti-M13 monoclonal antibody (diluted 1:5000 in
blocking buffer) was added and incubated at room temperature for
1 hr. Following incubation and washing again with the same
buffer, ABTS and H2O2 (30%, v/v) were added and the
absorbance was measured after a 1 hr incubation with mild
agitation at 405 nm with a microplate spectrophotometer
(Molecular Devices, Sunnyvale, CA).
In order to estimate the apparent dissociation constant for the
ALT5-8 clone, further ELISA experiments were performed with
extended phage concentrations. The data were fit to a Langmuir
isotherm using non-linear regression (SigmaPlot, San Jose, CA)
and the Kd,app was determined.
Kinetic Studies for Measuring Peptide Inhibition of the
Enzyme
ALT enzyme kinetics were measured to determine the impact of
the ALT5-8 peptide on the activity of the enzyme. Kinetic
experiments were performed in a coupled assay where the
pyruvate generated by ALT was reduced to lactate by LDH with
the concomitant oxidation of NADH. The depletion of NADH
was monitored by following its absorbance at 340 nm in UV-
transparent microplates. L-alanine and a-ketoglutarate concentra-
tions were varied from 2.5 to 10 mM and 0.5 to 10 mM
respectively. Initial concentrations of pyridoxal 59-phosphate,
NADH, and LDH were 0.1 mM, 0.25 mM and 47 U/L
respectively. The reactions were initiated by the addition of 330
Peptide-Based Biosensors
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solutions were prepared in 100 mM Tris-HCl buffer (pH 7.8), and
all kinetic trials were conducted 300 mLa t3 7uC.
The kinetic rates were fit to the bi-bi ping-pong mechanism
(Eqn. 1), to obtain estimates for kcat and the Michaelis constants
(KM) for L-alanine (A) and a-ketoglutarate (B).
Rate~
Etkcat½A ½B 
½A ½B zKM,A½B zKM,B½A 
ð1Þ
In order to determine if the peptide inhibited the enzyme as well
as the nature of the inhibition, the kinetics were repeated with
varying L-alanine concentrations at a constant concentration of a-
ketoglutarate (1 mM). Free ALT5-8 peptide inhibitor (I) was added
to the reactions at concentrations from 0–0.25 mM. The rates
plotted on a Lineweaver-Burk plot to understand the mode of
inhibition and the rates were also fit to the bi-bi ping-pong
equation with a competitive inhibitor (Eqn. 2):
Rate~
Etkcat½A ½B 
½A ½B zKM,A½B  1z
I
KI

zKM,B½A 
ð2Þ
QCM measurements
The QCM system consisted of a phase lock oscillator (PLO-10i,
Maxtek, East Syracuse, New York) and a frequency counter
(53131A, Agilent Technologies, Santa Clara, CA). The operation
of the setup was described previously [16]. Typically, a stable
baseline was achieved 1 hr after flow injection on a clean crystal at
a flow rate of 50 mL/min. After a stable baseline was obtained in
buffer, a peptide solution in the buffer was flowed to the cell.
Usually an abrupt change in the signal occurs with the valve
switching. In about 5 min, the new solution arrived at the cell and
caused a frequency change due to peptide binding to the crystal
surface. After the binding reached a steady state, buffer rinse was
then applied and no further change in frequency was observed.
Similar operations were performed for the addition of the cysteine
and ALT solutions, as well as solutions of other protein
competitors such as BSA and SA. All experiments were repeated
three times and similar results were obtained.
Electrochemical measurements
All electrochemical measurements were performed with a
mAUTOLAB potentiostat (Type III, FRA2, Metrohm Autolab,
Netherlands). A gold wire (dia. 1 mm) sealed in epoxy was used as
a working electrode and a platinum mesh was used as a counter
electrode. All potentials measured are reported versus a Ag/AgCl
reference electrode. Both cyclic voltammetry and EIS measure-
ments were conducted in a solution of 1 mM ferro/ferricyanide in
0.1 M sodium perchlorate.
CV and EIS were performed as previously described [16].
Briefly, the gold electrodes were prepared in 0.1 mM peptide
solution for 1 hr, followed by backfilling in 1 mM cysteine solution
for 2 hr to obtain a Au-Pep-Cys electrode. The Au-Pep-Cys
electrodes were incubated in ALT solution for 1 hr before CV and
EIS measurements. After each electrode preparation step, the
electrode is removed and placed into solutions of 1 mM ferro/
ferricyanide in 0.1 M NaClO4for analysis. Therefore, all the
electrochemical measurements were conducted in the ferro/
ferricyanide solution which eliminates the effect of any potential
viscosity differences between the sample solutions. CV experi-
ments were performed at a potential scan rate of 100 mV/s.
Impedance spectra were recorded over a frequency range of 0.1–
10
5 Hz. A single sinusoidal AC voltage of 10 mV was
superimposed on the open-circuit potential (typically 0.2 V vs.
Ag/AgCl). The impedance was recorded and a Nyquist plot was
obtained. A Randles circuit was used to fit the semi circular curves
in order to calculate the charge transfer resistance (RCT). The
change percentage of RCT is defined as
DRCT(%)~
RCTALT{RCTref
RCTref
|100%
where RCT
ref and RCT
ALT is the charge transfer resistance before
and after ALT binding.
Results
Selection and characterization of an ALT-binding peptide
A large commercially available phage display library was
biopanned over the immobilized ALT target protein. The yield of
phage binding to the plate increased each round after the second
(Table S1), even as the stringency of the selections was increased by
the addition of Tween 20. Twelve phage clones randomly selected
after the fifth round of selection were sequenced and the library was
found to have converged (10/12) to one predominant sequence,
ALT5-8, with a sequence of WHWRNPDFWYLK (Table 1). This
clone along with two other sequences obtained in the sequencing
(ALT4-3 and ALT5-9) were investigated using an ELISA assay to
assess the affinity of the selected phage clones for immobilized ALT.
The ALT4-3 and ALT5-9 clones were found to have a low affinity
for ALT similar to that of the M13 control phage, However, the
ALT5-8 clone exhibited a dose-dependent affinity for the ALT
protein (Figure 2) and was selected for further characterization.
Further ELISA experiments were performed with the ALT5-8
clone in order to determine the apparent affinity of the phage
particles for the ALT protein. A fit of this data to the Langmuir
isotherm (Figure 3) resulted in an apparent dissociation constant,
Kd,app of 85620 nM. Since the phage particles have approx-
imately 5 copies of the peptide per particle, it is possible that the
true affinity of the free peptide for the ALT protein will be
different from the apparent value due to the loss of the avidity
effect.
Measurement of peptide inhibition constant, KI
The ALT target protein has a large surface area for peptide
binding and the binding of the peptide in or near the active site of
the enzyme could possibly affect the catalytic properties of the
enzyme. Therefore, the impact of the peptide on the kinetics of the
ALT enzyme was investigated. In the absence of the peptide, the
kinetic data fit well to the bi-bi ping-pong equation (Eqn. 1) and the
following kinetic parameters were obtained: kcat=5.860.2 s
21,
Table 1. Sequences of the 12 selected phage clones obtained
following the fifth round of biopanning against ALT.
Name Amino acid sequence Frequency
ALT4-3 SNNLYPQRAVST 1/12
ALT5-8 WHWRNPDFWYLK 10/12
ALT5-9 LETEWDSLWYAP 1/12
doi:10.1371/journal.pone.0024948.t001
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(Figure S1) which are in agreement with previously published values
for the ALT enzyme [38,39,40,41].
Lineweaver-Burk plots of pyruvate production at varying
alanine concentrations are shown in Figure 4. The data suggests
that the ALT binding peptide is a competitive inhibitor for the
active site, with respect to alanine. The data were fit to the bi-bi
ping-pong mechanism with competitive inhibition (Eqn. 2) using
the kcat and KM values obtained in the absence of the peptide, and
the inhibition constant for the ALT5-8 peptide was found to be
KI=71617 nM.
Sensor preparation
In order to use the phage selected ALT peptide in the
development of an ALT biosensor, the peptide was modified with
a C-terminal cysteine for immobilization on gold. The preparation
of the sensor consisted of two steps: the immobilization of the
peptide and blocking of empty sites with free cysteine. Both steps
were monitored by QCM and electrochemical (CV and EIS)
measurements as shown in Figure 5. The immobilization of the
peptide resulted in a frequency drop in the QCM signal (Figure 5A)
due to mass loading, a current decrease in the CV (Figure 5B), and
an impedance increase in the EIS (Figure 5C) due to surface
blocking. The abrupt changes in the QCM noted by arrows
(Figure 5A) are due to pressure changes caused by valve switching.
This phenomenon was observed in all the experiments. All the
experiments were repeated three times with similar results each
time. All three techniques show the successful immobilization of
the peptides on the gold surface. Backfilling of the surface cysteine
did not cause any mass change in QCM since both the amount
and molecular weight of the blocking cysteine is small. However,
the backfilling did result in a current increase and a prominent
decrease in the impedance signal (smaller semi-circles). A similar
effect was observed in our previous studies [16] and in studies of
other modified surfaces [42]. The impedance decrease upon
backfilling can be explained by the easier charge transfer through
tunneling across the shorter cysteine. The charge transfer between
Fe(CN)6
4-/3- and the electrode occurs either by tunneling of
electrons through the surface self-assembled monolayer (SAM)
(peptide or cysteine), or through defects (unblocked sites) on the
surface [43]. The packing density of the immobilized peptide can
be calculated using the Sauerbrey equation [16]:
Dfm~{Cf|Dm ð3Þ
where Dfm is the frequency change due to mass loading, Dm is the
mass change at the QCM crystal surface and Cf=0.0566 Hz/(ng/
cm
2) for a 5 MHz AT-cut crystal at 20uC. The frequency drop of
the QCM due to peptide immobilization was about 21 Hz, which
Figure 2. Characterization of the selected ALT binding phage
clones using ELISA. ALT binding of the selected phage clones ALT5-8
(&), ALT4-3 (%), ALT5-9 (m) and M13 control phage (n) with varying
concentrations of phage particles ranging from 10
5 pfu to 10
11 pfu. All
measurements were performed in triplicate and error bars represent
standard deviations.
doi:10.1371/journal.pone.0024948.g002
Figure 3. Determination of the apparent dissociation constant
of ALT5-8 for ALT. ELISA experiments were performed in triplicate at
eight different phage concentrations and the data were fit by a
Langmuir isotherm (R
2=0.88) in order to estimate the apparent
equilibrium dissociation constant (Kd,app=85620 nM.).
doi:10.1371/journal.pone.0024948.g003
Figure 4. Lineweaver-Burk plots for the determination the of
the ALT enzyme inhibition by the ALT5-8 peptide. Varying
concentrations of peptide [I] were added as a function of initial ALT
concentration [E]. All data were collected in triplicate and R
2 values are
shown for the best fit line for each inhibitor concentration. A KI value of
71617 nM was obtained by fitting the entire data set simultaneously to
the bi-bi ping pong rate equation with competitive inhibition (Eqn. 2).
doi:10.1371/journal.pone.0024948.g004
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210 mol/cm
2 or
1.2610
14 molecule/cm
2 based on a peptide molecular weight of
1851 g/mol. The surface density of a similar sized troponin-
binding peptide immobilized on a gold surface has previously been
reported to be 7.4610
13 molecule/cm
2 [16]. Inamori et al. report a
surface density of 1.8610
12 to 1.8610
13 molecules/cm
2, depend-
ing on the attachment methods for an immobilized peptide on
gold [44]. The average cross-section of each peptide was
,0.8 nm
2 based on the surface density, which indicates a dense
packing mode of the immobilized peptides. The subsequent buffer
rinse caused a small frequency increase (the vertical drop observed
at the injection of buffer was caused by the sudden pressure
change due to valve switching), possibly due to the removal of
loosely bound peptide or the viscosity/density change of solutions.
ALT sensor operation
QCM, CV and EIS measurements validated the formation of
the peptide-based sensing layer. The same techniques were used to
demonstrate the affinity of the immobilized peptide for ALT, as
shown in Figure 6. Upon binding of ALT by the immobilized
peptide, a frequency decrease (Df=-31 Hz) in QCM (Figure 6A),
a current decrease in CV (Figure 6B), and a large impedance
increase in EIS (Figure 6C) were observed. No change was
observed for the buffer control in all three cases. All three
techniques indicate binding of ALT to the immobilized peptide.
To begin to study the selectivity of the peptide, similar
experiments were performed with streptavidin (SA) and bovine
serum albumin (BSA). Figure 7 shows the frequency change of Au-
Pep-Cys binding to SA, BSA and ALT. A small frequency change
of about -3 Hz was observed upon addition of SA and BSA, while
a frequency change of -31 Hz was observed with ALT. The small
frequency change seen with the control proteins might be due to
nonspecific binding of SA and BSA with unoccupied sites on the
surface or non-specific interactions with the peptide.
Although all three techniques demonstrate a signal change upon
the binding of ALT, the CV technique is a poor candidate for
quantitative measurement since the detection range is limited by
the fact that the current decreases upon target binding. For QCM
and EIS, response curves over a range of ALT concentrations are
shown in Figure 8. Both QCM (Figure 8A) and EIS (Figure 8B)
show a quantitative response to a range of ALT concentrations
and thus can be used as a sensing technique in quantitative ALT
measurements. The LOD obtained by QCM is 60 ng/mL, while
EIS had a LOD of 92 ng/mL. The sensitivity of the QCM system
was 8.960.9 Hz/(mg/mL), while the sensitivity of the EIS system
was 142612 impedance percentage change %/(mg/mL).
Based on the QCM response curve, the kinetic binding
constants can be deduced. As described previously [16], the
equilibrium dissociation constant, Kd, can be obtained from a plot
of frequency change, Dfeq, vs. Dfeq/C. Here, a dissociation constant
of Kd=2.01+0.06 mg/mL or 20.1+0.6 nM was calculated for
ALT binding on QCM.
Discussion
Our overall goal is to develop a streamlined platform for the
rapid development of new biosensors that can be used to detect
virtually any desired protein target. Phage display is a commonly
used method for identifying new binding motifs, and commercially
available kits make this process broadly accessible [4,7]. Biopan-
ning procedures are well documented, and new binding peptides
can usually be identified in a short period of time (1–2 weeks).
There are several detection methods available that can be used to
create a biosensor from a recognition peptide. We have chosen
Figure 5. Sensor preparation. A) the change in frequency during the
immobilization of peptide (Pep, 0.1 mM), rinsing (Rinse) and subse-
quent blocking with cysteine (Cys, 1 mM) on gold using QCM; B) CV of
the bare gold electrode (Au), the electrode with the peptide (Au-Pep),
and the blocked electrode (Au-Pep-Cys), C) EIS of bare gold (Au), the
peptide modified electrode (Au-Pep) and the blocked electrode (Au-
Pep-Cys) in a 1 mM solution of Fe(CN)6
4-/3- in 0.1 M NaClO4.
doi:10.1371/journal.pone.0024948.g005
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inexpensive, and can be readily incorporated into microfluidic
devices. In this manuscript, we demonstrate this process from start
to finish to create a new biosensor for the detection of ALT.
Figure 6. Sensor operation. A) QCM frequency change of Au-Pep-
Cys electrode in Buffer alone and in 10 mg/mL ALT, B) CV of Au-Pep-Cys
electrode before (Baseline) and after Buffer alone or ALT binding, C) EIS
of Au-Pep-Cys before (Baseline) and after Buffer alone or ALT binding.
After incubation in Buffer or 10 mg/mL ALT, the electrodes were
transferred to 1 mM solution of Fe(CN)6
4-/3- in 0.1 M NaClO4 for the EIS
measurements.
doi:10.1371/journal.pone.0024948.g006
Figure 7. Specificity of the ALT biosensor. The shift in QCM
frequency in response to injections of SA, BSA or ALT on the Au-Pep-Cys
modified crystal. The concentrations of all three solutions were 10 mg/
mL.
doi:10.1371/journal.pone.0024948.g007
Figure 8. Response curves of ALT binding. Measurements were
made using QCM (shown as absolute value of frequency change) (A)
and EIS (B). Each run was performed using a single electrode with
successive tests in ALT solutions from low to high concentration. The
apparent amount of bound ALT (NALT) for the QCM measurements was
calculated using Eqn. 3 and is shown on the right ordinate. Error bars
represent standard deviations obtained from triplicate measurements.
doi:10.1371/journal.pone.0024948.g008
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monitor its enzymatic activity [29,35,36]. This approach can be
very sensitive, but it is not a general platform for biosensor
development, and this approach needs to be redeveloped for each
new enzyme to be detected. We have chosen instead to directly
detect the presence of the protein using an evolved binding peptide,
andinthis waythedetectionmethod isgeneric and does not depend
on the enzymatic activity of the target protein. The phage display
library converged to a new binding sequence after 5 rounds of
biopanning (ALT5-8) and this peptide exhibited nanomolar affinity
for ALT when displayed on phage particles. We further explored
whether the peptide was binding near the active site of the enzyme
through enzyme inhibition studies. The peptide was found to be a
competitive inhibitor for ALT with a nanomolar inhibition
constant. However, the enzyme was still quite active even when
the peptide to protein ratio was at 2:1. Therefore, it is possible that
the enzyme is still active in the bound state, and future work will be
necessary to determine if a biosensor can be created based on
detecting the bound ALT activity instead of monitoring the mass
change that occurs upon binding of the enzyme.
Another concern with this approach is that peptides identified
using phage display may lose affinity for their target when they are
displayed on a different platform. There are, on average, 5 copies
of the ALT5-8 peptide on the surface of the M13 phage, and this
avidity effect gives rise to an apparent nanomolar dissociation
constant. This proved not be a significant problem as, when
peptides were immobilized on a solid surface, a true dissociation
constant for the ALT binding peptide remained in the nanomolar
scale range.
As we previously found with Troponin I, EIS appears to be the
optimal method for the electrochemical detection of the bound
target [16]. The procedure is straightforward, and high sensitivities
and low LOD values are obtained. The only downside to the EIS
technique is the need to measure the impedance signal in the
presence of a redox couple after the sample has been exposed to
the peptide sensing layer. But, the EIS technique produces a larger
linear sensing range than can be obtained with QCM and it is
more robust than QCM as it is less sensitive to environmental
perturbations.
The new ALT biosensor made from the ALT5-8 peptide
coupled with EIS detection had a LOD (0.092 mg/mL) close to the
normal level of ALT in human blood (0.1–0.7 mg/mL) [29].
Although we have demonstrated that the ALT5-8 peptide is
selective for ALT as compared to BSA and SA, further work will
be required to explore the performance of the biosensor in real
samples such as tissue culture media or plasma, and in the
presence of other potential interferents.
Although this approach will require further development before
it can be used to create a biosensor for clinical use, the use of
unstructured peptides obtained via phage display coupled with
electrochemical detection methods has several advantages com-
pared to other biosensor platforms described in the literature.
Alternative recognition elements such as antibodies are time
consuming and expensive to produce, and aptamer-based sensors
can require complex sample labeling and modification techniques
[45]. The unstructured peptides used in this approach can be
easily selected against virtually any target and are inexpensive to
synthesize, but they may suffer from poor selectivity in complex
solutions. Several transduction techniques are also available,
especially optical methods such as surface plasmon resonance
(SPR) [46] and Fo ¨rster resonance energy transfer (FRET) [47], but
EIS has the potential to be one of the most powerful and cost-
effective tools for biosensor development [48].
In summary, we have developed a general method for the
creation of new biosensors using short synthetic peptides obtained
via biopanning of a phage displayed library. The whole process
includes: target selection and immobilization, phage display to
select binding peptides, peptide synthesis with a terminal thiol,
QCM in-situ monitoring of peptide immobilization, and sensor
detection using electrochemical techniques (Figure 1). We have
demonstrated this approach by creating a new biosensor for a well-
known biomarker for hepatocellular toxicity, ALT. The new
biosensor had a LOD value just below the physiological
concentration of the target protein in human blood. Since both
phage display and EIS are widely used techniques, this general
approach to biosensor development is straightforward and can be
readily applied for the development of biosensors to detect almost
any desired protein target.
Supporting Information
Figure S1 Uninhibited ALT enzyme kinetic data. Kinetic
experiments were performed in a coupled assay where the
pyruvate generated by the ALT reaction was reduced to lactate
by LDH with the concomitant oxidation of NADH. Varying
concentrations of L-alanine (A) and a-ketoglutarate (B) were used,
and the data were fit to the bi-bi ping-pong mechanism (Eqn. 1)
using non-linear regression software (SigmaPlot). The Michaelis
constants for L-alanine and a-ketoglutarate were determined to be
8.060.9 mM and 0.09060.030 mM respectively with
kcat=5.860.2 s
21. All data were collected in triplicate and error
bars represent standard errors.
(TIF)
Table S1 Enrichments obtained by selecting the phage
displayed peptide library over immobilized ALT.
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